JenniferRuthBrownMDPhD

Oncology • Boston, MA

Hematologic Oncology

Assistant Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Brown is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brown's full profile

Already have an account?

Office
44 Binney St
# Dana-Far
Boston, MA 02115
Phone+1 617-632-4894

Fax+1 617-582-7909

Education & Training

Brigham and Women's HospitalResidency, Internal Medicine, 2017
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2004
Massachusetts General HospitalResidency, Internal Medicine, 1998 - 2001
Harvard Medical SchoolClass of 1998

Certifications & Licensure

MA State Medical License 2000 - 2026
MS State Medical License 2017 - 2021
American Board of Internal Medicine Hematology

Clinical Trials

Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma Start of enrollment: 2003 Dec 01
Completed
Phase 2
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma Start of enrollment: 2005 Feb 01
Completed
Phase 2
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies Start of enrollment: 2004 Aug 09
RECRUITING
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL Start of enrollment: 2006 May 01
Completed
Phase 1
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL Start of enrollment: 2007 Oct 01
Terminated
Phase 1
Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 01
Terminated
Phase 1
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Feb 01
Unknown status
Phase 2
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Start of enrollment: 2010 Mar 01
Completed
Phase 1, Phase 2
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
COMPLETED
PHASE2
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
COMPLETED
PHASE2
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
ACTIVE_NOT_RECRUITING
PHASE1
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2020 May 13
ACTIVE_NOT_RECRUITING
PHASE2
Understanding Chronic Lymphocytic Leukemia Start of enrollment: 1999 Sep 29
RECRUITING
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL Start of enrollment: 2020 Dec 15
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia.
Stephen Jun Fei Chong, Junyan Lu, Rebecca Valentin, Timothy Z Lehmberg, Jie Qing Eu
Molecular Cancer. 2025-03-03
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, Nicole Lamanna, Beenish S Manzoor
American Journal of Hematology. 2025-03-01
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQ...
Mazyar Shadman, Talha Munir, Tadeusz Robak, Jennifer R Brown, Brad S Kahl
Journal of Clinical Oncology. 2025-03-01

Abstracts/Posters

Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLL
Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...
Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL
Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers
Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia
Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)
Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)
Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Resu...
Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with InvestigatorÍs Choice of ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na¥ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
The Future of Chronic Lymphocytic Leukemia (CLL) Therapy
60th American Society of Hematology Annual Meeting - 12/3/2018
Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Clinical Trial of the STAT3 Inhibitor Pyrimethamine in Chronic Lymphocytic Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Clinical Trial of the STAT3 Inhibitor Pyrimethamine in Chronic Lymphocytic Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
17th International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma®
Physicians' Education Resource, LLC, New York, New York - 2/15/2013
Join now to see all

Press Mentions

Acalabrutinib-Venetoclax Prolongs Survival in Previously Untreated LeukemiaMarch 3rd, 2025
Acalabrutinib-Venetoclax with or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLLFebruary 25th, 2025
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed SettingsFebruary 4th, 2025
Join now to see all